Claims for Patent: 6,017,897

Summary for Patent: 6,017,897

Title:	Nucleic acid respiratory syncytial virus vaccines
Abstract:	Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
Inventor(s):	Li; Xiaomao (Thornhill, CA), Ewasyshyn; Mary E. (Willowdale, CA), Sambhara; Suryaprakash (Markham, CA), Klein; Michel H. (Willowdale, CA)
Assignee:	Pasteur Merieux Connaught Canada (Ontario, CA)
Application Number:	08/896,500
Patent Claims:	1. An immunogenic composition for in vivo administration to a host for the generation in the host of a protective immune response to RSV F protein, comprising a plasmid vector comprising: a first nucleotide sequence selected from the group consisting of a nucleic acid sequence having SEQ ID No: 1, a nucleic acid sequence having SEQ ID No: 3, a nucleic acid sequence encoding an RSV F protein having SEQ ID No: 2, and a nucleic acid sequence encoding an RSV F protein fragment having SEO ID No: 4; a promoter sequence operatively coupled to the first nucleotide sequence for expression of said RSV F protein or said RSV F protein fragment in the host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence and comprising a pair of splice sites to prevent aberrant mRNA splicing and to enhance the immunoprotective ability of said RSV F protein or said RSV F protein fragment when expressed in vivo from said vector in a host; and a pharmaceutically-acceptable carrier therefor. 2. The composition of claim 1 wherein said first nucleotide sequence encodes a full-length RSV F protein having SEO ID No: 2. 3. The composition of claim 1 wherein said first nucleotide sequence encodes a RSV F protein from which the transmembrane region is absent and having SEQ ID No: 4. 4. The composition of claim 1 wherein said promoter sequence is an immediate early cytomegalovirus promoter. 5. The composition of claim 1 wherein said second nucleotide sequence is that of rabbit .beta.-globin intron II.

Details for Patent 6,017,897

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-06-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-06-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-06-07